Industry News
Biotechnology Industry News
The FDA has rejected a rare blood…
The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through a newly launched priority voucher program.
Just as a disciplined soccer…
Just as a disciplined soccer player might pass on a hopeful shot in favor of better chance later on, the biopharma venture capital market reflected a preference for de-risked assts over platforms and predicted a
After a string of high-profile…
After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient well-being, particularly for those with rare diseases.
With sales of Immunocore’s…
With sales of Immunocore’s melanoma medicine steadily ticking up, an expanded label likely down the line and a longtime colleague no longer at her side, CEO Bahija Jallal, Ph.D., is mixing caution with ambition as
Messenger RNA specialist Moderna’s…
Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials.
Ultragenyx’s employees were…
Ultragenyx's employees were already braced for changes as the biopharma considered how to rebound from a pair of failed late-stage brittle bone disease trials.
Sanofi is replacing CEO Paul…
Sanofi is replacing CEO Paul Hudson with Merck KGaA leader Belén Garijo, M.D., Ph.D., after a series of R&D setbacks at the French pharma. Hudson will end his six-year run at Sanofi’s helm Feb. 17,
After scrapping one portion of the…
After scrapping one portion of the trial, Lundbeck’s intravenous monoclonal antibody has met the main goal of a phase 2b migraine prevention study, with multiple doses of the experimental treatment tied to a change in
Just months after laying off a…
Just months after laying off a quarter of its workforce to fund a phase 2 study of its bloodstream infection preventive treatment, Seres Therapeutics is pausing that investment and sending more employees to the exits.
BridgeBio is hoping that…
BridgeBio is hoping that infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in a form of dwarfism in children.
For all of the groundbreaking…
For all of the groundbreaking advancements in cancer treatment over the last decades, the first step for tackling almost all solid tumors is still surgery. If the cancer comes back, medicines like immunotherapies can then
Massachusetts’ largest life…
Massachusetts’ largest life science employer has put more than 630,000 square feet of office space on the sublease market as part of efforts to consolidate the Japanese company’s U.S. corporate hub at a new Cambridge
After the FDA’s surprise refusal…
After the FDA's surprise refusal to take up a review of Moderna's next-gen flu vaccine, the public disagreement between U.S. regulators and the mRNA specialist took another turn Wednesday.
Whisper it, but we may finally be…
Whisper it, but we may finally be seeing the IPO window reopening in 2026.
Madrigal Pharmaceuticals is…
Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra.
A phase 2 asthma study of Upstream…
A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week regimen achieving a Tezspire-like reduction in the annualized asthma exacerbation rate, the readout fell
The FDA specifically took issue…
The FDA specifically took issue with the trial's control arm, which incorporated a "licensed standard-dose seasonal influenza vaccine," per Moderna's press release.
In an effort to bolster Europe’s…
In an effort to bolster Europe’s biotech venture capital ecosystem, investment firms, research institutions and other stakeholders have launched the European Life Sciences Coalition.
Nektar Therapeutics is basking in…
Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic dermatitis, where the candidate successfully reduced the size and itchiness of patients’ eczema after 52
Evommune has aced its first major…
Evommune has aced its first major test as a public company, reporting phase 2a eczema data that caused its share price to jump 75% in premarket trading.